Overview

NeuroHope Therapeutics, Inc. is a pharmaceutical company co-founded by Clemson University bioengineering faculty. NeuroHope specializes in developing nanotherapeutics that can locally deliver drugs to damaged, diseased, or degenerating regions of the central nervous system. Each year, acute spinal cord injury (SCI) impacts approximately 17,000 new patients in the United States and 250-500,000 worldwide, while acute traumatic brain injury (TBI) affects approximately 2.5 million people in the United States and 10-60 million worldwide. Currently, there is no FDA-approved therapy for these patients. Therefore, our goal is to develop nanotherapeutics to reduce neuroinflammation, mitigate progressive neurodegeneration, increase functional recovery, and improve quality of life for people who are living with SCI and TBI.